{
    "clinical_study": {
        "@rank": "154951", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms\n      of improving survival and reducing the morbidity following allogeneic bone marrow\n      transplantation in patients with myelodysplastic syndrome and acute leukemia related to\n      Fanconi's anemia."
        }, 
        "brief_title": "Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia", 
        "condition": [
            "Fanconi's Anemia", 
            "Myelodysplastic Syndromes", 
            "Leukemia, Nonlymphocytic, Acute", 
            "Leukemia, Lymphocytic, Acute"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Fanconi Anemia", 
                "Fanconi Syndrome", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Leukemia, Myeloid, Acute", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body\n      radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Diagnosis of Fanconi's anemia with the family history and typical phenotype\n             including: Short stature Hypoplastic radii Skin pigmentation Renal anomalies\n             Chromosomal fragility\n\n          -  Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow\n             cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells\n\n          -  First complete remission following therapy for Fanconi's acute leukemia allowed\n\n          -  Must have related histocompatible donor No evidence of excessive in vitro chromosome\n             fragility typical of Fanconi's anemia Normal CBC and bone marrow"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "54 Years", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005892", 
            "org_study_id": "199/15100", 
            "secondary_id": [
                "UMN-MT-1985-01", 
                "UMN-MT-8501"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Allogeneic Bone Marrow Transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "keyword": [
            "Fanconi's anemia", 
            "acute leukemia", 
            "acute lymphocytic leukemia", 
            "acute myeloid leukemia", 
            "acute undifferentiated leukemia", 
            "adult acute lymphoblastic leukemia", 
            "adult acute lymphoblastic leukemia in remission", 
            "adult acute myeloid leukemia", 
            "adult acute myeloid leukemia in remission", 
            "aplastic anemia", 
            "childhood acute lymphoblastic leukemia", 
            "childhood acute lymphoblastic leukemia in remission", 
            "childhood acute myeloid leukemia", 
            "childhood acute myeloid leukemia in remission", 
            "de novo myelodysplastic syndrome", 
            "hematologic disorders", 
            "hematopoietic/lymphoid cancer", 
            "leukemia", 
            "myelodysplastic syndrome", 
            "oncologic disorders", 
            "previously treated myelodysplastic syndrome", 
            "rare disease", 
            "secondary myelodysplastic syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Fairview University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Fairview University Medical Center", 
            "last_name": "Daniel J. Weisdorf", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005892"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fairview University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2004"
    }, 
    "geocoordinates": {
        "Fairview University Medical Center": "44.98 -93.264"
    }
}